Immunostimulatory colloidal delivery systems for cancer vaccines

被引：26
作者：
Saupe, Anne [1 ]
McBurney, Warren [1 ]
Rades, Thomas [1 ]
Hook, Sarah [1 ]
机构：
[1] Univ Otago, Sch Pharm, Dunedin, New Zealand
来源：
EXPERT OPINION ON DRUG DELIVERY | 2006年 / 3卷 / 03期
关键词：
archaeosomes; cancer vaccine delivery; colloidal systems; immune stimulating complexes; liposomes; polymeric microparticles; polymeric nanoparticles; virus-like particles;
D O I：
10.1517/17425247.3.3.345
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Cancer vaccine delivery is a multidisciplinary scientific field that is currently undergoing rapid development. An important component of cancer vaccines is the development of novel vaccine delivery strategies, such as colloidal immunostimulatory delivery systems. The importance of formulation strategies for cancer vaccines can be explained by the poor immunogenicity of tumour antigens. Colloidal vaccine delivery systems modify the kinetics, body distribution, uptake and release of the vaccine. This review explores recent research that is directed towards more targeted treatments of cancer through to colloidal vaccine delivery systems. Widely investigated carrier systems include polymeric micro-and nanoparticles, liposomes, archaeal lipid liposomes (archaeosomes), immune-stimulating complexes and virus-like particles. These systems are evaluated in terms of their formulation techniques, immunological mechanisms of action as well as the potential and limitations of such colloidal systems in the field of cancer vaccines.
引用
收藏
页码：345 / 354
页数：10
相关论文
共 93 条
[1]   A block in virus-like particle maturation following assembly of murine leukaemia virus in insect cells [J].
Adamson, CS ;
Davies, A ;
Soneoka, Y ;
Nermut, M ;
Mitrophanous, K ;
Jones, IM .
VIROLOGY, 2003, 314 (02) :488-496
[2]   Recent advances on chitosan-based micro- and nanoparticles in drug delivery [J].
Agnihotri, SA ;
Mallikarjuna, NN ;
Aminabhavi, TM .
JOURNAL OF CONTROLLED RELEASE, 2004, 100 (01) :5-28
[3]   Immunogenicity and protectivity of a new liposomal hepatitis A vaccine [J].
Ambrosch, F ;
Wiedermann, G ;
Jonas, S ;
Althaus, B ;
Finkel, B ;
Gluck, R ;
Herzog, C .
VACCINE, 1997, 15 (11) :1209-1213
[4]   Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles [J].
Banerjee, T ;
Mitra, S ;
Singh, AK ;
Sharma, RK ;
Maitra, A .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 243 (1-2) :93-105
[5]   ISCOMs and other saponin based adjuvants [J].
Barr, IG ;
Sjölander, A ;
Cox, JC .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 32 (03) :247-271
[6]   Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs) [J].
Blutt, SE ;
Warfield, KL ;
O'Neal, CM ;
Estes, MK ;
Conner, ME .
VACCINE, 2006, 24 (08) :1170-1179
[7]   Preparation of coated nanoparticles for a new mucosal vaccine delivery system [J].
Borges, O ;
Borchard, G ;
Verhoef, JC ;
de Sousa, A ;
Junginger, HE .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 299 (1-2) :155-166
[8]   Nanoparticle and targeted systems for cancer therapy [J].
Brannon-Peppas, L ;
Blanchette, JO .
ADVANCED DRUG DELIVERY REVIEWS, 2004, 56 (11) :1649-1659
[9]   In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production [J].
Brewer, JM ;
Conacher, M ;
Satoskar, A ;
Bluethmann, H ;
Alexander, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (09) :2062-2066
[10]   Delivery of protein antigens to the immune system by fusion-active virosomes: A comparison with liposomes and ISCOMs [J].
Bungener, L ;
Huckriede, A ;
Wilschut, J ;
Daemen, T .
BIOSCIENCE REPORTS, 2002, 22 (02) :323-338
12345678910